In excess of 12.5 million cases of typhoid fever occur annually throughout the world (5) . The expected mortality rate without therapy of 15 to 30% (3, 13) can be reduced to very low levels with antimicrobial therapy. The conventional drug of choice worldwide has been chloramphenicol because of its excellent bioavailability by the oral route, its low cost, and its clinical efficacy (11, 17, 19) . Unfortunately, therapy with chloramphenicol has little effect on the recurrence of disease relapse or chronic intestinal carriage of Salmonella typhi posttherapy (9, 10) . Because of the drug's low cost, these limitations had been accepted by many public health officials and clinicians in the developing world until drug resistance began to occur. In some areas of the world, resistance of S. typhi to each of the three standard antityphoid drugs (chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole) has become common (1, 8) .
Between 2 and 4% of patients with typhoid fever become chronic intestinal carriers of S. typhi for more than 1 year (10) . Typhoid carriers are important to the epidemiology of this infection, in which humans represent the exclusive reservoir of the organism. New chemotherapeutic drugs are needed that would be more predictably effective in areas where resistance is reported and that, hopefully, would decrease the occurrence of posttreatment typhoid relapses and chronic intestinal carriage of the organism.
Because of its in vitro and in vivo activity against bacterial enteropathogens (8) , aztreonam was examined as an antityphoid drug in clinical studies with patients with typhoid fever. In two preliminary uncontrolled clinical trials, the drug ap-peared to be effective for the therapy of typhoid disease (7, 18 Patients were removed from the study if they had blood cultures positive for the infecting organism after 5 days of therapy or if they experienced a severe, adverse event during therapy.
To monitor for potential adverse drug effects, a complete blood count and serum chemistry tests (including serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, total bilirubin, alkaline phosphatase, creatinine, fasting blood glucose, total protein, albumin, sodium, and potassium) were performed pretreatment, on day 7, on the last day of therapy, and at the 7th day posttreatment follow-up. Antimicrobial susceptibility testing with the Salmonella isolates was performed with agar dilution to determine MICs (14) .
Serum samples were drawn at admission for antityphoid agglutinins (O and H), and a titer of anti-O agglutinin of -1:80 was considered to be positive.
Analysis of variance for continuous variables and chi-square and Mantel-Haenszel tests for discrete variables were used in the analyses, employing the SPSS/PC+ program.
The study was reviewed and approved by the Ethical Institutional Review Board of the Universidad Peruana 'Cayetano Heredia.' All patients included in the study gave written consent.
RESULTS
A total of 52 patients were enrolled in the trial. Eight patients were later removed from the study, because five patients had negative baseline cultures, and three patients elected not to enter the trial. A total of 44 patients, 22 in each group, with culture-proven typhoid fever were enrolled in the a Temperatures were taken each 6 h during therapy. Fever was defined as an oral temperature of >37.5°C. To be considered afebrile, the patient had to have a temperature of '37.5°C and be without fever thereafter during treatment.
"P < 0.001.
to withdraw from the trial without explanation on day 4. Each of these three patients was withdrawn from the trial and excluded from the efficacy analysis. Defervescence occurred more quickly in the subjects receiving chloramphenicol than in those receiving aztreonam. The average time from initiation of therapy until defervescence was 6.6 ± 3.58 days in the aztreonam group, with the corresponding time in the chloramphenicol group being 4.5 ± 2.3 days (P < 0.03). By analysis of variance, adjusting for sex, day of treatment, and culture positivity, there was a statistical difference between the durations of fever between the two treatment groups (P < 0.001). The number of febrile patients was greater on each day of therapy in the aztreonam group than in the chloramphenicol group (Table 2) . This difference was significant beginning with the fifth day of treatment. The difference in the persistence of fever in the groups was highly significant (P < 0.001). No patient in the chloramphenicol group was febrile after the eighth day, while 8 of 19 (42%) patients in the aztreonam group remained febrile on the ninth day of therapy. Four patients of the aztreonam group (21%) remained with fever through 10 days of therapy, when the study drug was changed to chloramphenicol.
Twenty-two of 22 (100%) patients receiving chloramphenicol were clinically cured, while 7 patients (32%) were declared treatment failures in the group receiving aztreonam (Table 3) elimination of organisms from blood than those in the chloramphenicol group. None of the 19 patients completing a course of aztreonam, compared with 7 of 22 patients receiving chloramphenicol, had a positive blood culture after 24 h of therapy (Table 4) (P < 0.01). The same difference, although less obvious, was seen for days 2 through 4 of therapy. Relapses did not occur in the aztreonam group. Stool cultures became negative more slowly than the blood cultures. At the end of treatment (days 1 and 2 posttreatment), 2 of 15 (13%) patients who completed their treatment in the aztreonam group and 1 of 22 (5%) patients of the chloramphenicol group had had a stool culture positive for Salmonella infection. One patient in each group had a stool culture positive for Salmonella infection at the seventh day of follow-up, and one patient in the chloramphenicol group was positive at the 14-day follow-up.
Adverse experiences in either group were unusual and mild. (1, 5, 6, 8) . In a number of the reports, multiresistant typhoid strains have been identified against which none of the standard antityphoid drugs (including ampicillin and trimethoprim-sulfamethoxazole) were active. This and the ineffectiveness of standard therapy (chloramphenicol) in preventing intestinal carriage of S. typhi or typhoid relapse make the search for effective antityphoid drugs essential. Among the new drugs being examined are those with in vitro activity against S. typhi and S. paratyphi, including broadspectrum cephalosporins, the new fluoroquinolones, and aztreonam (2, 6, 12, 15) . Two recent reports suggested that aztreonam might be of value in the treatment of typhoid fever (7, 18) . One of these studies was with children treated in a randomized clinical trial in Mexico City (18) , and the second was an open trial with adults treated in Egypt (7) . In 10 days of therapy and were declared treatment failures (P = 0.04). Two patients in the aztreonam group were excluded because of intestinal bleeding. If the three patients prematurely dropped from the study after being randomized to receive aztreonam are included in the analysis, the rate of failure for aztreonam increases to 7 of 22 (32%) (P < 0.01).
Aztreonam appeared to have a more rapid effect on elimination of the infecting Salmonella organisms from the bloodstream than chloramphenicol did. In 100% of the patients receiving aztreonam, the infecting S. typhi organisms were eradicated from blood cultures during the first day of treatment. This is in contrast to a culture positivity rate for day 1 blood cultures of 32% for the chloramphenicol-treated patients (P < 0.01). This may have been even more important, considering the higher rate of pretreatment blood culture positivity in the aztreonam group than in the chloramphenicol group (86 versus 54%, respectively; P < 0.05). Interestingly, the four patients declared treatment failures, with fever persisting throughout the 10 days of aztreonam treatment, had consistently negative blood cultures.
Comparing the present study with previous clinical trials carried out at this institution, the rate of cure for aztreonam was lower than that seen for standard therapy, but the bacteriologic response to aztreonam was superior. One possible explanation for the findings of the various studies is that aztreonam is able to clear Salmonella organisms from the blood of bacteremic patients, but it is less effective in eradication of the organism from the intracellular location characteristic of the later stages of typhoid infection. We speculate that aztreonam may not have adequately penetrated and concentrated within the intracellular tissues serving as the habitat of the infecting salmonellae.
Recent studies indicate that aztreonam shows a high degree of in vitro activity against enteric bacterial pathogens (8, 16). The drug has been shown, furthermore, to be effective in the treatment of bacterial enterocolitis of U.S. travelers to Mexico when given orally (4) . Further studies to examine the effect of aztreonam on other forms of bacterial enteric infection are indicated. Considering its rapid clearance from the bloodstreams of patients with typhoid fever, it is suggested that the value of the drug in treating nontyphoid Salmonella infections, such as Salmonella enteritidis gastroenteritis, with or without bacteremia, and extraintestinal infection, including central nervous system infection in young infants and systemic salmonellosis in patients infected with the human immunodeficiency virus, be determined.
